[Pharmaceutical Industry] Merck (MRK) vs. Roche (ROG / RHHBY) — A Thorough Comparison of Business Growth Potential

[The Empire of Keytruda vs. The Dual-Wielding of Diagnostics and Therapeutics — Reading the Next Decade of Mega-Pharma]

Record Date: May 10, 2026
Merck Stock Price: Approx. $111 (NYSE / December Fiscal Year-End / US GAAP)
Roche Stock Price: Approx. $50.93 (ADR: RHHBY, NASDAQ OTC) / Approx. 320 Swiss Francs (ROG.SW, SIX Swiss Exchange / December Fiscal Year-End / IFRS)

* Both companies have a December fiscal year-end, so direct comparison is possible.
* Currencies differ (Merck is in USD, Roche is in CHF; ADR is in USD).
* Accounting standards differ (Merck uses US GAAP, Roche uses IFRS).
* Merck refers to the U.S.-based Merck & Co., Inc. (known as MSD in Japan and Europe). It is a separate company from the German Merck KGaA (EMR).
* Roche's Q1 2026 earnings were negatively impacted by foreign exchange (strong Swiss Franc), creating a divergence between constant-currency growth and reported figures.

Author's Focus Points

• Attention Level: Merck ★★★☆☆ / Roche ★★★★☆

• I have a slightly stronger interest in Roche. It is the world's only mega-pharma that possesses both pharmaceuticals and diagnostics, and in Q1 2026, the pharmaceutical division showed solid growth of 7% excluding currency effects. I am focusing on its stable shareholder returns, which include 38 consecutive years of dividend increases, and its next-generation pipeline for obesity, Alzheimer's, and cancer immunotherapy. On the other hand, the biggest focus for Merck is its growth strategy after the Keytruda patent expiration (2028).

① Current Stock Price and Valuation Comparison

Merck (MRK)

• Stock Price: Approx. $111

• P/E (Fwd): Approx. 12-13x

• Dividend Yield: Approx. 3.5% ($3.08 annually)

• Market Cap: Approx. $277.4 billion (Approx. 42 trillion yen)

• Non-GAAP EPS (Full Year 2025): $8.98

• Fiscal Year-End: December (US GAAP)

Roche (ROG / RHHBY)

• Stock Price (ADR): Approx. $50.93

• P/E (TTM): Approx. 20x

• Dividend Yield: Approx. 3.1% (9.80 Swiss Francs annually)

• Market Cap: Approx. $334 billion (Approx. 50 trillion yen)

• 38 consecutive years of dividend increases

• Fiscal Year-End: December (IFRS)

Merck appears undervalued in terms of valuation with a Fwd PER of 12-13x, but this already accounts for the risk of Keytruda's patent expiration (2028). Roche has a relatively high PER of around 20x for the pharmaceutical sector, but it is valued for the stable earnings of its diagnostics business and the depth of its pipeline. The dividend yield for both companies is an attractive 3%+, and Roche has a track record of 38 consecutive years of dividend increases.

② Comparison of Recent Financial Results

Merck — FY2025 (Full-Year Results) and Q1 2026

• FY2025 Full Year

• Revenue: $65 billion (+1% YoY)

• KEYTRUDA/KEYTRUDA QLEX Revenue: $31.7 billion (+7% YoY)

• GARDASIL/GARDASIL 9 Revenue: $5.2 billion (-39% YoY)

• WINREVAIR Revenue: $1.4 billion (rapid growth as a new drug)

• CAPVAXIVE Revenue: $760 million

• Animal Health Revenue: $6.4 billion (+8% YoY)

• GAAP EPS: $7.28

• Non-GAAP EPS: $8.98

• Net Income: $18.25 billion (+6.6% YoY)

• Q1 2026 (January-March 2026)

• Revenue: $16.3 billion (+5% YoY)

• Non-GAAP EPS: -$1.28 (recorded a $9 billion one-time expense related to the Sedera acquisition)

• Oncology and Animal Health drove growth

• FY2026 Full-Year Guidance: Raised median revenue to $66.4 billion

• Highlights of the Pipeline

• Subcutaneous KEYTRUDA (KEYTRUDA QLEX) receives FDA approval, improving administration convenience

• Approximately 80 Phase 3 trials are currently underway

• Positive results to be announced for 18 Phase 3 trials during 2025

Roche — Fiscal Year Ending December 2025 (Full-Year Results Forecast) and Q1 2026

• Full Year Ending December 2025

• Roche has already announced the details of its full-year financial results in February 2026

• Stock price has risen 119% over the past year and 32% year-to-date

• Q1 2026 (January–March 2026)

• Group sales: +6% growth excluding currency effects (-5% in Swiss Franc base)

• Pharmaceutical division sales: 11.5 billion Swiss Francs (+7% excluding currency effects)

• Diagnostics division sales: 3.3 billion Swiss Francs (+3% excluding currency effects, +5% excluding China)

• The strength of the Swiss Franc against the dollar had a negative impact on exchange rates

• Full-Year Guidance for Fiscal Year Ending December 2026

• Sales growth rate: Mid-single digits (confirmed)

• Core EPS growth rate: High-single digits (confirmed)

• Dividend: Policy to continue dividend increases (9.80 Swiss Francs, 38 consecutive years of dividend increases)

③ Comparison of Business Structure and Mid-Term Plans

Merck

One of the world's leading research-driven biopharmaceutical companies. Its cancer immunotherapy, Keytruda (pembrolizumab), is an overwhelming flagship product, accounting for approximately 49% of total company revenue.

Strengths

• Keytruda is one of the world's best-selling drugs ($31.7 billion annually)

• Approval of the subcutaneous formulation (KEYTRUDA QLEX) improves patient convenience and expands the market

• WINREVAIR (pulmonary arterial hypertension) is growing rapidly at $1.4 billion annually

• The Animal Health business ($6.4 billion annually) serves as a stable second pillar

• A massive pipeline with approximately 80 Phase 3 trials

Challenges

• Keytruda's U.S. patent expires in 2028, with biosimilar entry expected

• GARDASIL (cervical cancer vaccine) sales in China have dropped sharply (-39%)

• GAAP EPS was negative in Q1 2026 due to the $9 billion acquisition cost of Seagen

• High dependence on Keytruda (approx. 49% of sales) represents a concentration risk

Mid-term Strategy

• Keytruda lifecycle management (subcutaneous administration, expansion of combination therapy indications)

• Global rollout of WINREVAIR (pulmonary arterial hypertension)

• Development of next-generation ADCs (antibody-drug conjugates) in the oncology field

• Portfolio diversification through multiple large-scale acquisitions

Roche

One of the world's largest healthcare companies, headquartered in Basel, Switzerland. It is the only mega-pharma in the world with two divisions: Pharmaceuticals and Diagnostics.

Strengths

• Integrated pharmaceutical and diagnostic model enables treatment proposals based on companion diagnostics

• Diversified portfolio in oncology (Tecentriq, Avastin, etc.), immunology (Ocrevus), and ophthalmology (Vabysmo)

• Pharmaceutical division saw solid growth of +7% excluding currency effects in Q1 2026

• Stable shareholder returns with 38 consecutive years of dividend increases

• Roche Diagnostics holds the top global market share in in-vitro diagnostics

Challenges

• Strong Swiss Franc weighs on dollar-denominated earnings (-5% in Q1 2026 on a Franc basis)

• Headwinds for the diagnostics division due to healthcare pricing reforms in China

• Biosimilar erosion of legacy blockbuster products (Herceptin, Avastin, etc.) has peaked, but the growth rate of new products is key

• Valuation is relatively high for the pharmaceutical sector with a P/E ratio of approximately 20x

Mid-term Strategy

• Accelerating development of obesity treatments (GLP-1 receptor agonists such as CT-996)

• Strengthening the pipeline for Alzheimer's disease treatments (such as tralucumab)

• Development of next-generation cancer immunotherapies (bispecific antibodies, ADCs)

• Deepening the precision medicine approach by integrating diagnostics and therapeutics

④ Differences in the business strategies of the two companies

While Merck and Roche are both among the top 5 global mega-pharmaceutical companies, their business structures and growth strategies are clearly different.

Approach to expanding business portfolios
Merck relies on three pillars: human pharmaceuticals, vaccines, and animal health, but approximately 49% of its sales are concentrated in a single product, Keytruda. Roche operates two businesses: Pharmaceuticals and Diagnostics, with diagnostics accounting for about 22% of sales. This integrated 'diagnostics x therapeutics' model is a unique strength exclusive to Roche, enabling the joint proposal of companion diagnostics and therapeutic drugs.

Investment policy
Merck actively pursues large-scale M&A (e.g., Acceleron, Verona Pharma, Cidara) and is rushing to diversify its portfolio in preparation for the patent expiration of Keytruda. Roche tends to prioritize internal pipeline development over acquisitions, while focusing on its own R&D and accelerating expansion into new areas such as obesity and neuroscience.

Market Expansion Strategy
Merck is promoting the expansion of Keytruda indications in the North American market, while the recovery of GARDASIL in China remains a challenge. Roche, based in Europe and North America, is responding to price reforms in the diagnostic business in China while accelerating the launch of new products globally following the entry of biosimilars.

This difference results in distinct growth stories: for Merck, it is a 'race against time against the clear risk of Keytruda's patent expiration,' and for Roche, it is 'stable growth that steadily cultivates the next generation of pillars through an integrated model of diagnostics and treatment.'

⑤ Business Environment Scenario for the Next 3 Years

*This is merely an organization of the business environment and not a stock price forecast.

Tailwind Scenario

• The market for cancer immunotherapy continues to expand, with successive approvals for new indications and combination therapies.

• The market for GLP-1 receptor agonists (obesity treatment) expands explosively.

• Impact on Merck: Subcutaneous administration of Keytruda becomes widespread, boosting sales to a peak before patent expiration. WINREVAIR and CAPVAXIVE grow as the second and third pillars.

• Impact on Roche: The obesity treatment pipeline succeeds and grows into a major product. The portfolio gains further depth with the approval of an Alzheimer's treatment.

Base Scenario

• Advances in cancer treatment continue, but price pressure also intensifies.

• The impact of Keytruda biosimilar entry (from 2028 onwards) gradually becomes apparent.

• Impact on Merck: Performance remains solid until 2028, but it is unclear whether new products can fully compensate for the subsequent decline in sales. EPS growth rate slows down.

• Impact on Roche: Maintains mid-single-digit sales growth and high-single-digit EPS growth. Stability in the diagnostics business supports the entire group.

Headwind Scenario

• Strengthening of drug price reduction policies (US IRA, European reference pricing systems).

• Failure of clinical trials for major pipelines.

• Impact on Merck: Risk of a significant decline in EPS after 2028 as products to compensate for the drop in Keytruda sales fail to develop.

• Impact on Roche: Growth expectations fade due to failures in the obesity and Alzheimer's pipelines. However, the stock-based revenue of the diagnostics business acts as a buffer.

⑥ Why I am focusing on Roche

1. A unique business model of 'Diagnostics x Therapeutics'

Roche is the only mega-pharma company that operates both pharmaceuticals and in-vitro diagnostics at a world-class level. Its integrated model, which identifies patients through companion diagnostics and provides its own therapeutic drugs, is a structural strength in the era of precision medicine.

2. Stable shareholder returns with 38 consecutive years of dividend increases

The dividend is 9.80 Swiss francs per year (a yield of approximately 3.1%), marking 38 consecutive years of increases. This is one of the best shareholder return track records among mega-pharma companies, providing peace of mind for long-term holding.

3. Diversity in next-generation pipelines

The company is advancing multiple large-scale pipelines in parallel, including obesity treatments (GLP-1 receptor agonists), Alzheimer's disease treatments, and next-generation cancer immunotherapies. Compared to Merck, which is dependent on a single product, the high number of 'at-bats' serves as risk diversification.

Counter-perspectives and rebuttal points

• Merck's forward P/E ratio of 12-13x is significantly cheaper than Roche's P/E of approximately 20x, and the risk of Keytruda's patent expiration may be excessively priced in.

• Keytruda's subcutaneous formulation (KEYTRUDA QLEX) could serve as a differentiator from biosimilars, potentially mitigating the decline in sales after patent expiration.

• Merck's WINREVAIR ($1.4 billion annually) and CAPVAXIVE ($760 million annually) are growing rapidly, and the next pillars of growth are steadily developing.

• Merck's dividend yield of approximately 3.5% exceeds Roche's approximately 3.1%, making it more attractive in terms of income.

• Since Roche is denominated in Swiss francs, currency risk (especially a strong Swiss franc) poses an additional risk for yen-based and dollar-based investors.

⑦ Competitor map for both companies (6 companies)

Direct competitors (2 companies)

• Bristol Myers Squibb (BMY) — Competes head-on with Keytruda through its cancer immunotherapy 'Opdivo'. Also competes with Merck and Roche in multiple myeloma (successor to Revlimid) and cardiovascular areas.

• AstraZeneca (AZN) — Its indications in the oncology field (Tagrisso, Imfinzi) overlap with Merck's Keytruda, and it competes with Roche's next-generation cancer treatment pipeline through ADCs (Enhertu, in partnership with Daiichi Sankyo).

Broad competitors (2 companies)

• Novartis (NVS) — A fellow Swiss rival. Business areas partially overlap in heart failure (Entresto), breast cancer (Kisqali), and gene therapy. While it does not have a diagnostics business, it is accelerating investment in precision medicine.

• Eli Lilly (LLY) — Has achieved explosive growth with obesity treatments (Mounjaro, Zepbound), making it the biggest competitor to Roche's obesity pipeline. It is also developing products that compete with Merck in the oncology field.

Overseas or alternative competitors (2 companies)

• AbbVie (ABBV) — Currently strengthening its immunology and oncology segments through post-Humira portfolio restructuring. Significant growth in Skyrizi, Rinvoq, etc., competing with Merck and Roche in therapeutic areas.

• Daiichi Sankyo (4568) — A Japanese pharmaceutical company gaining global attention for its ADC (Enhertu). Accelerating global expansion through a partnership with AstraZeneca, it is a competitor to Merck and Roche's next-generation pipelines in the oncology field.

*This is intended solely to assist in understanding the business environment and is not a recommendation for other stocks.

⑧ Common Risk Factors

• Strengthening of drug price reduction policies (US IRA, European reference pricing systems)

• Patent expirations of major products and entry of biosimilars

• Risk of failure in large-scale clinical trials

• Foreign exchange risk (USD, CHF, emerging market currencies)

• Regulatory approval delays or safety concerns

• Impact of US-China trade friction on pharmaceutical and diagnostic supply chains

• Disruption risk from emerging biotech companies and AI-driven drug discovery

⑨ Summary by Reader Interest

*This does not recommend any specific investment actions.

• Growth-Oriented: Roche has a rich pipeline in obesity, Alzheimer's, and next-generation cancer immunotherapy, offering many medium- to long-term growth drivers. Merck faces the risk of slowing growth after Keytruda's patent expiration (2028), making the ramp-up speed of next-generation products the key.

• Stability-Oriented: Roche's 'Diagnostics + Therapeutics' model is superior in terms of business diversification, and its track record of 38 consecutive years of dividend increases underscores its stability. Merck's Animal Health business is a stable second pillar, but its high dependence on Keytruda risks undermining stability.

• Dividend-Oriented: Merck's dividend yield of approximately 3.5% exceeds Roche's approximately 3.1%. Both companies have a stable dividend track record as mega-pharma firms.

• Value-Oriented: Merck's Fwd P/E of 12-13x is significantly cheaper than Roche's approximately 20x. However, the reason for the low valuation (Keytruda patent expiration) is clear, and the justification for that valuation depends on the investor's perspective.

Record Data

Merck (MRK)

• Stock Price: Approx. $111

• Forward P/E: Approx. 12-13x

• Dividend Yield: Approx. 3.5% ($3.08 annually)

• Market Cap: Approx. $277.4 billion

• FY2025 Revenue: $65 billion (+1% YoY)

• FY2025 KEYTRUDA Revenue: $31.7 billion (+7% YoY)

• FY2025 GARDASIL Revenue: $5.2 billion (-39% YoY)

• FY2025 Non-GAAP EPS: $8.98

• Q1 2026 Revenue: $16.3 billion (+5% YoY)

• FY2026 Full-Year Revenue Guidance Median: $66.4 billion

• Phase 3 Trials: Approx. 80 ongoing

Roche (ROG / RHHBY)

• Stock Price (ADR): Approx. $50.93

• TTM P/E: Approx. 20x

• Dividend Yield: Approx. 3.1% (38 consecutive years of dividend growth)

• Market Cap: Approx. $334 billion

• Q1 2026 Pharmaceuticals Division Revenue: 11.5 billion CHF (+7% at constant exchange rates)

• Q1 2026 Diagnostics Division Revenue: 3.3 billion CHF (+3% at constant exchange rates)

• Q1 2026 Group Revenue Growth: +6% at constant exchange rates

• 2026 Guidance: Mid-single-digit revenue growth, high-single-digit core EPS growth

• Annual Dividend: 9.80 CHF/share

Data Sources

• Merck 2025 Full-Year Financial Results (February 6, 2026)

• Merck Q1 2026 Earnings Release

• StockAnalysis.com MRK

• TradingView MRK

• Roche Q1 2026 Earnings Release (April 2026)

• Investing.com Roche Holding ADR (RHHBY)

• Yahoo! Finance RHHBY

• Digrin.com ROG.SW Dividend History

Request

Please follow and like this post. If there are any stocks you would like me to compare, please let me know in the comments section.

Important Notice

This article does not recommend the buying or selling of any specific financial products, nor does it constitute investment advice. The information in this article is current as of the date of recording and may differ from the latest information. Please make investment decisions at your own risk. While we have taken every precaution to ensure the accuracy of the figures and data provided, we do not guarantee their completeness. Please note that direct comparisons of monetary amounts require caution due to differences in currency (USD/CHF). Merck's Q1 2026 GAAP EPS shows a loss due to one-time expenses related to the Sedera acquisition, but the business remains robust on a non-GAAP basis.

Bonus: Today's Terminology Explained

Biosimilar - What is it?

It is the biopharmaceutical version of a 'generic drug.' While generics for standard drugs (chemically synthesized drugs) can be exact copies of the ingredients, biopharmaceuticals are made using living cells, so an exact copy cannot be created. Because they are 'look-alikes' (similar), they are called 'biosimilars.' When the patents for major biopharmaceuticals like Keytruda expire, these biosimilars enter the market, causing price competition and reducing sales of the original drug. Since the U.S. patent for Merck's Keytruda expires in 2028, the subsequent entry of biosimilars is Merck's biggest management challenge.